Adalimumab biosimilar (Hetero Drugs)
阿达木单抗生物类似药（Hetero Drugs）
Report date: 2022/01/14 13:23:58
Base Information
Drug NameAdalimumab biosimilar (Hetero Drugs)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesHetero Drugs Ltd
China Registration ClassN/A
Develop Information
Other Information
ATC Code
Related LinksN/A